Provention Bio’s for PRV-031 (teplizumab) granted PRIME Designation by the EMA
Provention Bio (NASDAQ: PRVB), a clinical-stage biopharmaceutical Company, announced the grant of a PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA), for PRV-031 (teplizumab), indicated for the prevention or delay of clinical type 1 diabetes (T1D) in individuals at-risk of developing the disease....
